SightfileU.S. market data from official filings

4D MOLECULAR THERAPEUTICS IN (FDMT)

Name: 4D MOLECULAR THERAPEUTICS IN (FDMT) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001650648 · EDGAR filings · Updated 2026-07-20

4D MOLECULAR THERAPEUTICS IN (FDMT) has reported institutional ownership of 96.8%, with 150 institutional managers holding positions valued at $470.9M per the latest 13F reporting period.

Institutional ownership

96.8%

Institutional managers

150

Reported 13F value

$470.9M

Insider activity

19 trans.

−$134.0K net selling

Latest updates

2026-07-20 — Current report (8-K) filed
2026-07-14 — Insider transaction reported (Form 4)
2026-07-10 — Notice of proposed sale filed (Form 144)
2026-07-09 — Notice of proposed sale filed (Form 144)
2026-07-02 — Insider transaction reported (Form 4)
2026-06-30 — Notice of proposed sale filed (Form 144)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, 4D MOLECULAR THERAPEUTICS IN has 150 institutional holders and institutional ownership of 96.8%.

Insider activity

Insiders reported 19 transactions (0 buys, 10 sells) across 3 reporting insiders, with a net reported value of −$134.0K.

Related companies

BETA BIONICS INC (BBNX) · MINIMED GROUP INC (MMED) · SANA BIOTECHNOLOGY INC (SANA) · BIOVENTUS (BVS) · AVALO THERAPEUTICS INC (AVTX) · CRESCENT BIOPHARMA INC. (CBIO)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-20.